Identifying ERBB2 activating mutations in HER2-negative breast cancer: Clinical impact of institute-wide genomic testing and enrollment in matched therapy trials
Pedro Exman, Ana C. Garrido-Castro, Melissa E. Hughes, Rachel A. Freedman, Tianyu Li, Lorenzo Trippa, Brittany L. Bychkovsky, Romualdo Barroso-Sousa, Simona Di Lascio, Colin MacKichan, Max R. Lloyd, Max Krevalin, Ethan Cerami, Margaret S. Merrill, Rebecca Santiago, Lindsey Crowley, Nicole Kuhnly, Janet Files, Neal I. Lindeman, Laura E. MacConaillPriti Kumari, Sara M. Tolaney, Ian E. Krop, Ron Bose, Bruce E. Johnson, Cynthia X. Ma, Deborah A. Dillon, Eric P. Winer, Nikhil Wagle, Nancy U. Lin
Dive into the research topics of 'Identifying ERBB2 activating mutations in HER2-negative breast cancer: Clinical impact of institute-wide genomic testing and enrollment in matched therapy trials'. Together they form a unique fingerprint.